Athira Pharma Advances Phase 2/3 LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients Following Independent, Unblinded Interim Analysis
October 17, 2022 07:00 ET
|
Athira Pharma, Inc.
Results support potential clinically meaningful activity of fosgonimeton without background therapy and mitigate program risk Updated study well powered for primary endpoint with addition of fewer...
Athira Pharma Provides Update on Plans for Ongoing LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients
September 06, 2022 07:00 ET
|
Athira Pharma, Inc.
Adapting study to focus on the evaluation of fosgonimeton monotherapy Conducting an independent, unblinded interim analysis to confirm sample size for primary endpoint of Global Statistical Test...
Athira Pharma Reports Second Quarter 2022 Financial Results and Recent Clinical and Corporate Updates
August 15, 2022 16:05 ET
|
Athira Pharma, Inc.
Presented clinical and preclinical data at Alzheimer’s Association International Conference 2022 Strong balance sheet to support clinical development pipeline BOTHELL, Wash., Aug. 15, 2022 (GLOBE...
Athira Pharma Presents Data from ACT-AD Phase 2 Proof-of-Concept Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients at the Alzheimer's Association International Conference 2022
August 03, 2022 11:28 ET
|
Athira Pharma, Inc.
Additional data showed numerical improvement in activities of daily living (ADCS-ADL23), a protocoled secondary endpoint and a functional measure of independence Plasma biomarker data in a...
Athira Pharma Presents Preclinical Data at the Alzheimer's Association International Conference 2022
August 02, 2022 15:30 ET
|
Athira Pharma, Inc.
Fosgo-AM, the active metabolite of Fosgonimeton (ATH-1017), demonstrates neuroprotective effects in primary neuron culturesNew orally available small molecule positive modulators of HGF/MET reverse...
Athira Pharma to Present Clinical and Preclinical Data at Alzheimer’s Association International Conference 2022
July 25, 2022 07:00 ET
|
Athira Pharma, Inc.
BOTHELL, Wash., July 25, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
Athira Pharma Announces Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
June 22, 2022 07:00 ET
|
Athira Pharma, Inc.
Primary endpoint of change in biomarker ERP P300 latency was not statistically significant for the full study population as combination of fosgonimeton and standard-of-care (AChEIs) given together...
Athira Pharma Announces Formation of Scientific Advisory Board Comprised of Renowned Leaders in Neurology Research
June 07, 2022 07:00 ET
|
Athira Pharma, Inc.
BOTHELL, Wash., June 07, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
Shareholders Approve the Election of All Three Athira Director Nominees at 2022 Annual Meeting
May 19, 2022 12:06 ET
|
Athira Pharma, Inc.
BOTHELL, Wash., May 19, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
Athira Issues Statement in Response to Richard A. Kayne’s Suspension of His Proxy Contest
May 16, 2022 16:49 ET
|
Athira Pharma, Inc.
Athira Board Unanimously Recommends Shareholders Vote “FOR” its Highly Qualified Nominees – Joseph Edelman, John M. Fluke, Jr. and Grant Pickering – on the WHITE proxy card BOTHELL, Wash., May 16,...